Status:

COMPLETED

Neuroprotection Impact of Cyclosporin A in Cerebral Infarction

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Stroke

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

The main objective of this study is to determine whether a single injection of CsA after intravenous thrombolysis can significantly decreased the volume of cerebral infarction at day 30 ± 15 assessed ...

Eligibility Criteria

Inclusion

  • Patients age ≥ 18 years and \<85 years
  • Male or female,
  • Patients with cerebral infarction of less than 4:30H,
  • NIHSS score between 6 and 18
  • Identification of a carotid artery occlusion in the territory in MRI
  • Consent of participation signed by the patient or, if it is unable to give the family or someone you trust if it is present.
  • Patient beneficiary of a social security system.

Exclusion

  • Known hypersensitivity to cyclosporin A or castor oil, polyoxyethylene
  • Patient in St. John's wort, stiripentol, bosentan or rosuvastatin
  • History of immunosuppression recent (\<6 months): cancer, lymphoma, positive serology for HIV, hepatitis, ...
  • Known hepatic (prothrombin time \<50%)
  • Patients treated with sulfonylureas or nicorandil
  • Patients treated with dopamine, adrenaline, noradrenaline or isoprenalin
  • Uncontrolled hypertension defined as systolic blood pressure greater than 185mm Hg and a diastolic pressure above 110 mmHg,
  • Cardiogenic shock defined by systolic blood pressure below 80 mm Hg
  • Contraindication to thrombolysis: History of AIC in the three months history of intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, arteriovenous malformation
  • Presumption of septic embolism or aortic dissection or pericardial effusion.
  • Recent biopsy or surgery within 3 months
  • Head injury less than 3 months
  • Known bleeding diathesis, taking anticoagulants with INR\> 1.2
  • Hypoglycemia (blood glucose below 0.5 mmol / l)
  • Known renal, creatinine greater than 130 Mu / L
  • Recent Lumbar puncture \<7days
  • Conditions prior psychiatric or neurological deficit does not allow objective analysis of disability
  • History of ischemic stroke or hemorrhagic
  • History of epilepsy and taking antiepileptic
  • Exclusion criteria Imaging
  • Structured hypodensity scanner compatible with recent ischemic stroke
  • Hematoma
  • Other lesions (tumor or inflammatory cerebral venous thrombosis)
  • The scanner Contraindications: allergy to iodine or major renal creatinine\> 130μl or MRI referred to above
  • Women of childbearing age, pregnant or not recognized effective contraception
  • Patients in the measure of legal protection.

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

126 Patients enrolled

Trial Details

Trial ID

NCT01527240

Start Date

October 1 2009

End Date

December 1 2013

Last Update

May 28 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospices Civils de Lyon

Lyon, France, 69002